| | PRESS RELEASE NicOx announces initiation of phase 3 trial for HCT 3012 in osteoarthritis (Site not responding. Last check: 2007-10-30) |
 | | HCT 3012 is a novel, proprietary, nitric oxide-donating derivative of naproxen, which NicOx aims to develop as the drug-of-choice for osteoarthritis patients, particularly those with coexisting hypertension (high blood pressure). |
 | | The trial is designed to demonstrate that HCT 3012 is superior to placebo and as effective as naproxen in relieving the signs and symptoms of osteoarthritis, in addition to showing that HCT 3012 has no detrimental effect on blood pressure. |
 | | Mean systolic blood pressure was also lower in the HCT 3012 treatment groups at the end of 6 weeks, compared to baseline, in contrast to no change with placebo and an increase with rofecoxib and naproxen. |
| www.marketwire.com /mw/release_html_b1?release_id=104506 (1255 words) |